NasdaqGS:COLLPharmaceuticals
Collegium Pharmaceutical (COLL): Updated Guidance and Buybacks Spark Fresh Valuation Focus After Q2 Results
If you’re wondering what to do with Collegium Pharmaceutical (COLL) in light of their latest earnings report, you’re not alone. The company just posted its second quarter numbers, revealing a drop in earnings compared to last year, but also surprised many by raising its full year revenue guidance. In addition, Collegium provided an update on its aggressive share buyback program, which could speak volumes about management’s confidence or at least their current preferred use of cash. These...